JP2016536327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536327A5 JP2016536327A5 JP2016537322A JP2016537322A JP2016536327A5 JP 2016536327 A5 JP2016536327 A5 JP 2016536327A5 JP 2016537322 A JP2016537322 A JP 2016537322A JP 2016537322 A JP2016537322 A JP 2016537322A JP 2016536327 A5 JP2016536327 A5 JP 2016536327A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- functional fragment
- neutralizing antibody
- days
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims 47
- 102100006400 CSF2 Human genes 0.000 claims 29
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 29
- 241000288906 Primates Species 0.000 claims 28
- 200000000018 inflammatory disease Diseases 0.000 claims 21
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 19
- 229960000485 methotrexate Drugs 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 15
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 14
- 108090001123 antibodies Proteins 0.000 claims 14
- 102000004965 antibodies Human genes 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 230000003472 neutralizing Effects 0.000 claims 12
- 201000008482 osteoarthritis Diseases 0.000 claims 12
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 11
- 201000001263 psoriatic arthritis Diseases 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 10
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 9
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 9
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 9
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 6
- 230000003432 anti-folate Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000004052 folic acid antagonist Substances 0.000 claims 6
- 229940079593 drugs Drugs 0.000 claims 5
- 208000004235 Neutropenia Diseases 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 3
- 238000011087 biopharmaceutical technology Methods 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 230000003442 weekly Effects 0.000 claims 3
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 claims 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004171 Hydroxychloroquine Drugs 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 206010033661 Pancytopenia Diseases 0.000 claims 2
- 229960001940 Sulfasalazine Drugs 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 102100015911 ATIC Human genes 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims 1
- 229960001334 Corticosteroids Drugs 0.000 claims 1
- 229960000304 Folic Acid Drugs 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- 206010018987 Haemorrhage Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 102100002074 MTHFR Human genes 0.000 claims 1
- 101710033932 MTHFR Proteins 0.000 claims 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 claims 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 206010029305 Neurological disorder Diseases 0.000 claims 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims 1
- 108010045040 Phosphoribosylaminoimidazolecarboxamide Formyltransferase Proteins 0.000 claims 1
- 102100009534 TNF Human genes 0.000 claims 1
- 229960000278 Theophylline Drugs 0.000 claims 1
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 1
- 108010067449 Thymidylate Synthase Proteins 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 229940121359 adenosine receptor antagonists Drugs 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 229960000074 biopharmaceuticals Drugs 0.000 claims 1
- 230000000740 bleeding Effects 0.000 claims 1
- 231100000319 bleeding Toxicity 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 230000003364 opioid Effects 0.000 claims 1
- 230000001185 psoriatic Effects 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871900P | 2013-08-30 | 2013-08-30 | |
| US201361871904P | 2013-08-30 | 2013-08-30 | |
| US61/871,900 | 2013-08-30 | ||
| US61/871,904 | 2013-08-30 | ||
| PCT/EP2014/068489 WO2015028657A1 (en) | 2013-08-30 | 2014-09-01 | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042267A Division JP2020109108A (ja) | 2013-08-30 | 2020-03-11 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016536327A JP2016536327A (ja) | 2016-11-24 |
| JP2016536327A5 true JP2016536327A5 (pt) | 2017-10-12 |
Family
ID=51454704
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537322A Pending JP2016536327A (ja) | 2013-08-30 | 2014-09-01 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP2020042267A Pending JP2020109108A (ja) | 2013-08-30 | 2020-03-11 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP2022076303A Pending JP2022105160A (ja) | 2013-08-30 | 2022-05-02 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
| JP2024103720A Pending JP2024123249A (ja) | 2013-08-30 | 2024-06-27 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042267A Pending JP2020109108A (ja) | 2013-08-30 | 2020-03-11 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP2022076303A Pending JP2022105160A (ja) | 2013-08-30 | 2022-05-02 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
| JP2024103720A Pending JP2024123249A (ja) | 2013-08-30 | 2024-06-27 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10745475B2 (pt) |
| EP (2) | EP3889178A1 (pt) |
| JP (4) | JP2016536327A (pt) |
| KR (3) | KR20220045064A (pt) |
| CN (2) | CN105705518A (pt) |
| AU (3) | AU2014314053C1 (pt) |
| BR (1) | BR112016003293A8 (pt) |
| CA (1) | CA2922251C (pt) |
| ES (1) | ES2860480T3 (pt) |
| MX (2) | MX2016002177A (pt) |
| RU (1) | RU2714919C2 (pt) |
| WO (1) | WO2015028657A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150080004A (ko) | 2003-05-15 | 2015-07-08 | 앰피오 파마슈티컬스 인코퍼레이티드 | Ｔ-세포 매개성 질환의 치료 방법 |
| WO2013055734A1 (en) | 2011-10-10 | 2013-04-18 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
| WO2016028790A1 (en) | 2014-08-18 | 2016-02-25 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| CN109219616B (zh) * | 2016-09-19 | 2022-10-21 | 天境生物科技(杭州)有限公司 | Gm-csf抗体及其用途 |
| WO2018144773A1 (en) | 2017-02-01 | 2018-08-09 | Yale University | Treatment of diuretic resistance |
| AU2019205936B2 (en) | 2018-01-05 | 2022-09-15 | Novo Nordisk A/S | Methods for treating IL-6 mediated inflammation without immunosuppression |
| EP3765630B1 (en) * | 2018-03-14 | 2024-08-28 | Indiana University Research And Technology Corporation | Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS59147297A (ja) | 1983-02-10 | 1984-08-23 | 株式会社日立製作所 | 原子炉圧力容器の耐震構造 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| US5747032A (en) | 1990-08-10 | 1998-05-05 | Amrad Corporation Limited | Monoclonal antibody to human granulocyte macrophage colony stimulating factor |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| CN100360184C (zh) | 1995-07-27 | 2008-01-09 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| AU2001232267A1 (en) | 2000-02-14 | 2001-08-20 | Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases | Remedies for hepatitis c |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| ATE444308T1 (de) | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon |
| ES2311094T3 (es) | 2002-02-27 | 2009-02-01 | Immunex Corporation | Composicion estabilizada de tnfr-fc que comprende arginina. |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| CA2501786C (en) | 2002-10-30 | 2015-02-17 | Genentech, Inc. | Inhibition of il-17 production |
| JP4879884B2 (ja) | 2004-04-12 | 2012-02-22 | メディミューン，エルエルシー | 抗−ｉｌ−９抗体製剤及びその使用法 |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| KR20070095949A (ko) | 2004-12-16 | 2007-10-01 | 제넨테크, 인크. | 자가면역 장애의 치료 방법 |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| CN103342751B (zh) | 2005-04-18 | 2015-12-23 | 安进研发（慕尼黑）股份有限公司 | 人粒细胞巨噬细胞集落刺激因子的抗体中和剂 |
| HUE058876T2 (hu) | 2005-05-18 | 2022-09-28 | Morphosys Ag | Anti-GM-CSF antitestek és felhasználásuk |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| PT1981909T (pt) | 2006-02-08 | 2017-01-18 | Morphotek Inc | Péptidos antigénicos do gm-csf e anticorpos contra o gm-csf |
| PT2423230E (pt) | 2006-03-27 | 2013-08-26 | Medimmune Ltd | Membro de ligação para o recetor de gm-csf |
| SG176503A1 (en) * | 2006-11-21 | 2011-12-29 | Kalobios Pharmaceuticals Inc | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| US7951368B2 (en) | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PT2215119E (pt) | 2007-11-13 | 2013-02-11 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem |
| AU2009243184B2 (en) | 2008-04-28 | 2015-06-04 | Humanigen, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| UA102097C2 (ru) | 2008-04-29 | 2013-06-10 | Амген Рисерч (Мюнхен) ГмбХ | Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17 |
| ES2685895T3 (es) | 2008-12-22 | 2018-10-15 | The University Of Melbourne | Tratamiento del dolor |
| WO2010128035A1 (en) | 2009-05-05 | 2010-11-11 | Morphosys Ag | Treatment for multiple sclerosis |
| US20120121580A1 (en) | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| CA2783715A1 (en) | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| CN107693791B (zh) | 2010-02-26 | 2022-06-07 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| CA2851322C (en) * | 2011-10-10 | 2020-03-31 | Medimmune Limited | Treatment for rheumatoid arthritis with gm csfr alpha antibodies |
| JP2015533806A (ja) | 2012-09-20 | 2015-11-26 | モルフォシス・アー・ゲー | 関節リウマチの治療 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| JP6339578B2 (ja) * | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 |
| JP6346389B1 (ja) | 2016-08-03 | 2018-06-20 | 古河電気工業株式会社 | 金属粒子含有組成物 |
-
2014
- 2014-09-01 AU AU2014314053A patent/AU2014314053C1/en active Active
- 2014-09-01 ES ES14758384T patent/ES2860480T3/es active Active
- 2014-09-01 MX MX2016002177A patent/MX2016002177A/es unknown
- 2014-09-01 US US14/913,578 patent/US10745475B2/en active Active
- 2014-09-01 CN CN201480047403.XA patent/CN105705518A/zh active Pending
- 2014-09-01 EP EP21161450.8A patent/EP3889178A1/en active Pending
- 2014-09-01 JP JP2016537322A patent/JP2016536327A/ja active Pending
- 2014-09-01 CN CN202410511905.9A patent/CN118178647A/zh active Pending
- 2014-09-01 CA CA2922251A patent/CA2922251C/en active Active
- 2014-09-01 RU RU2016109944A patent/RU2714919C2/ru active
- 2014-09-01 KR KR1020227010431A patent/KR20220045064A/ko not_active IP Right Cessation
- 2014-09-01 EP EP14758384.3A patent/EP3039039B1/en active Active
- 2014-09-01 BR BR112016003293A patent/BR112016003293A8/pt not_active Application Discontinuation
- 2014-09-01 KR KR1020167007575A patent/KR20160044035A/ko not_active IP Right Cessation
- 2014-09-01 WO PCT/EP2014/068489 patent/WO2015028657A1/en active Application Filing
- 2014-09-01 KR KR1020247017478A patent/KR20240090993A/ko active Search and Examination
-
2016
- 2016-02-18 MX MX2021010472A patent/MX2021010472A/es unknown
-
2020
- 2020-03-11 JP JP2020042267A patent/JP2020109108A/ja active Pending
- 2020-06-12 AU AU2020203917A patent/AU2020203917A1/en not_active Abandoned
- 2020-08-17 US US16/995,617 patent/US11795216B2/en active Active
-
2022
- 2022-05-02 JP JP2022076303A patent/JP2022105160A/ja active Pending
-
2023
- 2023-08-04 AU AU2023210647A patent/AU2023210647A1/en active Pending
-
2024
- 2024-06-27 JP JP2024103720A patent/JP2024123249A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536327A5 (pt) | ||
| Castañeda et al. | Adult-onset Still's disease: advances in the treatment | |
| RU2016109944A (ru) | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков | |
| Genovese et al. | Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study | |
| Church et al. | Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders | |
| JP6657089B2 (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| JP2019531273A5 (pt) | ||
| Lopalco et al. | Canakinumab efficacy in refractory adult-onset PFAPA syndrome. | |
| AU2015313827C1 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP2018515493A5 (pt) | ||
| Bargagli et al. | Cytokine modulators in the treatment of sarcoidosis | |
| Zeng et al. | Antibody therapies in autoimmune inflammatory myopathies: promising treatment options | |
| CN1229113C (zh) | 用于治疗自身免疫性疾病的药物组合物 | |
| van Vollenhoven | New therapeutic approaches in rheumatoid arthritis | |
| Leng et al. | Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study | |
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗ＩＬ－α抗体 | |
| JP2020045351A (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| Combe et al. | Double-blind comparison of Etanercept and Sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving Sulphasalazine | |
| Chaplin et al. | P132 Redefining refractory disease in RA and adult polyarticular JIA: a Delphi consensus study | |
| Mallol | Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis | |
| Mease et al. | IL-17 inhibition in spondyloarthritis: a targeted approach in psoriatic arthritis | |
| Panasyuk et al. | SAT0186 Tocilizumab Improved of the Quality of the Life Patients with Severe/Moderate RA (Lornet Study) | |
| Kishimoto | S-5: A novel IL-6 mRNA stability protein, Arid5A which is involved in IL-6 dependent autoimmunity | |
| Islam et al. | Biological therapy for Rheumatoid Arthritis an update | |
| Goutet-Postel et al. | on April 8, 2016-Published by |